Serological markers of Chlamydia pneumoniae infection in men and women and subsequent coronary events: The Scottish Heart Health Study cohort

European Heart Journal

Volumn 23, Issue 4, 2002, Pages 301-307

  Tavendale, R ^a   Parratt, D ^a   Pringle, S D ^a   A'Brook, R ^a   Tunstall Pedoe, H ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

Chlamydia pneumoniae infection; Coronary artery disease; Epidemiology; Immune complexes

Indexed keywords

IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY;

ADULT; ANTIBODY TITER; ANTIGEN ANTIBODY COMPLEX; ARTICLE; CASE CONTROL STUDY; CHLAMYDOPHILA PNEUMONIAE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY RISK; FEMALE; FOLLOW UP; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; SEROLOGY;

ANTIBODIES, BACTERIAL; ANTIGEN-ANTIBODY COMPLEX; ANTIGENS, BACTERIAL; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CHLAMYDOPHILA INFECTIONS; CHLAMYDOPHILA PNEUMONIAE; CONFIDENCE INTERVALS; CORONARY ARTERIOSCLEROSIS; FEMALE; HUMANS; MALE; MIDDLE AGED; ODDS RATIO;

EID: 0036487230     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1053/euhj.2001.2778     Document Type: Article

References (34)

1. Weissberg PL. Atherogenesis: Current understanding of the causes of atheroma. Heart 2000; 83: 247-52.
2. Wong Y-K, Gallagher PJ, Ward ME. Chlamydia pneumoniae and atherosclerosis. Heart 1999; 81: 232-8.
3. Saikku P, Leinonen M, Mattila M et al. Serological evidence of an association of a novel chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction. Lancet 1988; ii: 983-5.
4. Kuo C-C, Shor A, Campbell LA, Fukushi H, Patton DL, Grayston JT. Demonstration of Chlamydia pneumoniae in atherosclerotic lesions of coronary arteries. J Infect Dis 1993; 167: 841-9.
5. Kuo C-C, Gown AM, Benditt EP, Grayston JT. Detection of Chlamydia pneumoniae in aortic lesions of atherosclerosis by immunocytochemical stain. Arterioscler Thromb 1993; 13: 1501-4.
6. Muhlestein JB, Hammond EH, Carlquist JF et al. Increased incidence of Chlamydia species within the coronary arteries of patients with symptomatic atherosclerotic versus other forms of cardiovascular disease. J Am Coll Cardiol 1996; 27: 1555-61.
7. Gupta S, Leatham EW, Carrington D, Mendall MA, Kaski JC, Camm AJ. Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction. Circulation 1997; 96: 404-7.
8. Gurfinkel E, Bozovich G, Daroca A, Beck E, Mautner B for the ROXIS study group. Randomised trial of roxithromycin in non-Q-wave coronary syndromes: ROXIS pilot study. Lancet 1997; 350: 404-7.
9. Anderson JL, Muhlestein JB, Carlquist J et al. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease and serological evidence for Chlamydia pneumoniae infection. The azithromycin in coronary artery disease: Elimination of myocardial infection with chlamydia (ACADEMIC) study. Circulation 1999; 99: 1540-7.
10. Smith WCS, Crombie IK, Tavendale R, Irving JM, Kenicer MB, Tunstall-Pedoe H. The Scottish Heart Health Study; objectives and development of methods. Health Bull 1987; 45: 211-7.
11. Tunstall-Pedoe H for WHO MONICA project principal investigators. The World Health Organization MONICA Project (Monitoring Trends and Determinants in Cardiovascular Disease): A major international collaboration. J Clin Epidemiol 1988; 41: 105-14.
12. Smith WCS, Crombie IK, Tunstall-Pedoe H. Ayrshire and Arran coronary prevention programme - Baseline risk factor survey. Health Bull 1989; 47: 227-33.
13. Carstairs V, Morris R. Deprivation and Health in Scotland. Aberdeen: Aberdeen University Press, 1991.
14. Tunstall-Pedoe H, Kuulasmaa KK, Amouyel P, Arveiler D, Rajakangas AM, Pajak A. Myocardial infarction and coronary deaths in the World Health Organization MONICA Project - Registration procedures, event rates, and case fatality rates in 38 populations from 21 countries in 4 continents. Circulation 1994; 90: 583-612.
15. Casali P, Bossus A, Carpentier NA, Lambert PH. Solid phase immunoassay or radioimmunoassay for the detection of immune complexes based on their recognition by conglutinin: Conglutinin binding test. Clin Exp Immunol 1977; 29: 342-54.
16. Tunstall-Pedoe H, Woodward M, Tavendale R, A'Brook R, McCluskey MK. Comparison of the prediction by 27 different factors of coronary heart disease and death in men and women of the Scottish Heart Health Study: Cohort study. 1998 BMJ; 315: 722-9.
17. Nieto FJ, Folsom AR, Sorlie PD, Grayston JT, Wang S-P, Chambless LE for the Atherosclerosis Risk in Communities (ARIC) study investigators. Chlamydia pneumoniae infection and incident coronary heart disease. The Atherosclerosis Risk in Communities Study. Am J Epidemiol 1999; 150: 149-56.
18. Ridker PM, Kundsin RB, Stampfer MJ, Poulin S, Hennekens CH. Prospective study of Chlamydia pneumoniae IgG seropositivity and risks of future myocardial infarction. Circulation 1999; 99: 1161-4.
19. Strachan DP, Carrington D, Mendall MA et al. Relation of Chlamydia pneumoniae serology to mortality and incidence of ischaemic heart disease over 13 years in the Caerphilly prospective heart disease study. BMJ 1999; 318: 1035-40.
20. Wald NJ, Law MR, Morris JK, Zhou X, Wong Y, Ward ME. Chlamydia pneumoniae infection and mortality from ischaemic heart disease: Large prospective study. BMJ 2000; 321: 204-7.
21. Danesh J, Whincup P, Walker M et al. Chlamydia pneumoniae IgG titres and coronary heart disease: Prospective study and meta-analysis. BMJ 2000; 321: 208-13.
22. Ridker PM, Hennekens CH, Buring JE, Kundsin R, Shih J. Baseline IgG antibody titres to Chlamydia pneumoniae, Helicobacter pylori, herpes simplex virus, and cytomegalovirus and the risk for cardiovascular disease in women. Ann Intern Med 1999; 131: 573-7.
23. Maass M, Bartels C, Engel PM, Mamat U, Sievers HH. Endovascular presence of viable Chlamydia pneumoniae is a common phenomenon in coronary artery disease. J Am Coll Cardiol 1998; 31: 827-32.
24. Puolakkainen M, Kuo C-C, Shor A, Wang S-P, Grayston JT, Campbell LA. Serological response to Chlamydia pneumoniae in adults with coronary arterial fatty streaks and fibrolipid plaques. J Clin Microbiol 1993; 31: 2212-4.
25. Davidson M, Kuo C-C, Middaugh JP et al. Confirmed previous infection with Chlamydia pneumoniae (TWAR) and its presence in early coronary atherosclerosis. Circulation 1998; 98: 628-33.
26. Wong Y-K, Dawkins KD, Ward ME. Circulating Chlamydia pneumoniae DNA as a predictor of coronary artery disease. J Am Coll Cardiol 1999; 34: 1435-9.
27. Dechend R, Maass M, Gieffers J et al. Chlamydia pneumoniae infection of vascular smooth muscle and endothelial cells activates NF-κB and induces tissue factor and PAI-1 expression. Circulation 1999; 100; 1369-73.
28. Rodel J, Woytas M, Groh A et al. Production of basic fibroblast growth factor and interluekin 6 by human smooth muscle cells following infection with Chlamydia pneumoniae. Infect Immun 2000; 68: 3635-41.
29. Moazed TC, Kuo C-C, Grayston JT. Murine models of Chlamydia pneumoniae infection and atherosclerosis. J Infect Dis 1997; 175: 883-90.
30. Fong IW, Chiu B, Viira E, Fong MW, Jang D, Mahony J. Rabbit model for Chlamydia pneumoniae infection. J Clin Microbiol 1997; 35: 48-52.
31. Torgano G, Cosentini R, Mandelli C et al. Treatment of Helicobacter pylori and Chlamydia pneumoniae infections decreases fibrinogen plasma level in patients with ischemic heart disease. Circulation 1999; 99: 1555-9.
32. Leinonen M, Linnanmaki E, Mattila K et al. Circulating immune complexes containing chlamydial lipopolysaccharide in acute myocardial infarction. Microb Pathog 1990; 9: 67-73.
33. Saikku P, Leinonen M, Tenkanen L et al. Chronic Chlamydia pneumoniae infection as a risk factor for coronary heart disease in the Helsinki Heart Study. Ann Int Med 1992; 116: 273-8.
34. Glader CA, Boman J, Saikku P et al. The proatherogenic properties of lipoprotein(a) may be enhanced through the formation of circulating immune complexes containing Chlamydia pneumoniae-specific IgG antibodies. Eur Heart J 2000; 21: 639-46, doi:10.1053/euhj.1999.1775.